Advertisement

Hormones

, Volume 13, Issue 4, pp 458–475 | Cite as

The role of ghrelin in weight-regulation disorders: Implications in clinical practice

  • Solomis Solomou
  • Márta Korbonits
Review

Abstract

Ghrelin, an orexigenic protein with a unique lipid chain modification, is considered to be an important gut-brain signal for appetite control and energy balance. The ghrelin receptor, growth-hormone secretagogue receptor type 1a, is able to bind acylated ghrelin. The first recognised effect of ghrelin was the induction of growth hormone release from the somatotroph cells of the anterior pituitary. Moreover, by acting on vagal afferents or centrally, ghrelin can activate hypothalamic arcuate neurons that secrete the orexigenic peptides neuropeptide Y and agouti-related peptide, and inhibit the anorexigenic neurons secreting pro-opiomelanocortin and α-melanocyte-stimulating hormone. The orexigenic signalling pathway of ghrelin involves adenosine monophosphate-activated protein kinase. It has been proposed that ghrelin can also increase dopaminergic transmission from the ventral tegmental area to the nucleus accumbens, leading to augmentation of afferent reward signals. Present evidence suggests that ghrelin plays an important role in obesity, eating disorders, and cachexia, as well as in regulating appetite and energy balance in healthy individuals. In pathological states, ghrelin can be lower than normal as is seen in obese individuals, or can be higher than normal as has been reported for Prader-Willi syndrome, anorexia nervosa, bulimia nervosa, and certain types of cachexia. In the future, the application of compounds targeting the ghrelin pathway could involve the use of pharmacotherapies of ghrelin agonists, antagonists or inverse agonists, neutralisation of ghrelin by vaccines and spiegelmers, desacyl ghrelin analogues, as well as inhibitors of the GOAT enzyme which attaches the lipid modification to desacyl ghrelin to synthetise ghrelin.

Key Words

Anorexia Ghrelin GHSR Obesity Prader-Willi syndrome 

References

  1. 1.
    Leite-Moreira AF, Rocha-Sousa A, Henriques-Coelho T 2007 Cardiac, skeletal, and smooth muscle regulation by ghrelin. In: L Gerald (ed) Vitam Horm, Academic Press; pp, 207–238.Google Scholar
  2. 2.
    van der Velde M, Delhanty P, van der Eerden B, van der Lely AJ, van Leeuwen J 2007 Ghrelin and Bone. In: L Gerald (ed) Vitam Horm, Academic Press; pp, 239–258.Google Scholar
  3. 3.
    Fuglsang J 2007 Ghrelin in pregnancy and lactation. In: L Gerald (ed) Vitam Horm, Academic Press; pp, 259–284.Google Scholar
  4. 4.
    Tena-Sempere M 2007 Ghrelin and reproduction: ghrelin as novel regulator of the gonadotropic axis. In: L Gerald (ed) Vitam Horm, Academic Press; pp, 285–300.Google Scholar
  5. 5.
    Kemp BA, Howell NL, Gildea JJ, Keller SR, Padia SH, 2013 Intrarenal ghrelin receptors regulate ENaC-dependent sodium reabsorption by a cAMP-dependent pathway. Kidney Int 84: 501–508.PubMedGoogle Scholar
  6. 6.
    Altinova AE, Törüner FB, Aktürk M, et al, 2006 Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Horm Res 65: 295–299.PubMedGoogle Scholar
  7. 7.
    Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K, 2008 Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci 53: 2215–2221.PubMedGoogle Scholar
  8. 8.
    Freda PU, Reyes CM, Conwell IM, Sundeen RE, Wardlaw SL, 2003 Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J Clin Endocrinol Metabol 88: 2037–2044.Google Scholar
  9. 9.
    Kadoglou NPE, Lampropoulos S, Kapelouzou A, et al, 2010 Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease-KOZANI STUDY. Transi Res 155: 238–246.Google Scholar
  10. 10.
    Libè R, Morpurgo PS, Cappiello V, et al, 2005 Ghrelin and adiponectin in patients with Cushing’s disease before and after successful transsphenoidal surgery. Clin Endocrinol (Oxf) 62: 30–36.Google Scholar
  11. 11.
    Monajemzadeh M, Mokhtari S, Motamed F, et al, 2013 Plasma ghrelin levels in children with cystic fibrosis and healthy children. Arch Med Sci 9: 93–97.PubMedGoogle Scholar
  12. 12.
    Nahata M, Muto S, Oridate N, et al, 2012 Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease. Am J Physiol Gastrointest Liver Physiol 303: G42–G53.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Nweneka C, Prentice A, 2011 Helicobacter pylori infection and circulating ghrelin levels — A systematic review. BMC Gastroenterol 11: 7.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Pinsker JE, Ondrasik D, Chan D, et al, 2011 Total and acylated ghrelin levels in children with poor growth. Pediatr Res 69: 517–521.PubMedGoogle Scholar
  15. 15.
    Pöykkö SM, Kellokoski E, Hörkkö S, et al, 2003 Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52: 2546–2553.PubMedGoogle Scholar
  16. 16.
    Schöfl C, Horn R, Schill T, et al, 2002 Circulating ghrelin Levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 87: 4607–4610.PubMedGoogle Scholar
  17. 17.
    Selimoglu MA, Altinkaynak S, Ertekin V, Akcay F, 2006 Serum ghrelin levels in children with celiac disease. J Clin Gastroenterol 40: 191–194.PubMedGoogle Scholar
  18. 18.
    Yilmaz H, Gerdan V, Kozaci D, et al, 2012 Ghrelin and adipokines as circulating markers of disease activity in patients with Takayasu arteritis. Arthritis Res Ther 14: R272.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Kojima M, Hosoda H, Date Y, et al, 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656–660.Google Scholar
  20. 20.
    Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL, 2008 Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132: 387–396.PubMedGoogle Scholar
  21. 21.
    Hosoda H, Kojima M, Matsuo H, Kangawa K, 2000 Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279: 909–913.PubMedGoogle Scholar
  22. 22.
    Heppner KM, Piechowski CL, Müller A, et al, 2013 Both acyl and des-acyl ghrelin regulate adiposity and glucose metabolism via CNS ghrelin receptors. Diabetes 63: 122–131.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Leung P-K, Chow KBS, Lau P-N, et al, 2007 The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal 19: 1011–1022.PubMedGoogle Scholar
  24. 24.
    Gnanapavan S, Kola B, Bustin S, et al, 2002 The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87: 2988–2988.PubMedGoogle Scholar
  25. 25.
    Lango Allen H, Estrada K, Lettre G, et al, 2010 Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467: 832–838.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Ogiso K, Asakawa A, Amitani H, Inui A, 2011 Ghrelin and anorexia nervosa: A psychosomatic perspective. Nutrition 27: 988–993.PubMedGoogle Scholar
  27. 27.
    Amini P, Wadden D, Cahill F, et al, 2012 Serum acylated ghrelin is negatively correlated with the insulin resistance in the CODING study. PLoS ONE 7: e45657.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Tong J, Prigeon RL, Davis HW, et al, 2010 Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 59: 2145–2151.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Tschop M, Smiley DL, Heiman ML, 2000 Ghrelin induces adiposity in rodents. Nature 407: 908–913.PubMedGoogle Scholar
  30. 30.
    Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al, 2006 Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116: 1983–1993.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Cummings DE, Purneil JQ, Frayo RS, et al, 2001 A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714–1719.PubMedGoogle Scholar
  32. 32.
    Arafat AM, Weickert MO, Adamidou A, et al, 2013 The impact of insulin-independent, glucagon-induced suppression of total ghrelin on satiety in obesity and type 1 diabetes mellitus. J Clin Endocrinol Metab 98: 4133–4142.PubMedGoogle Scholar
  33. 33.
    Abizaid A, Liu Z-W, Andrews ZB, et al, 2006 Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 116: 3229–3239.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Skibicka KP, Shirazi RH, Rabasa-Papio C, et al, 2013 Divergent circuitry underlying food reward and intake effects of ghrelin: Dopaminergic VTA-accumbens projection mediates ghrelin’s effect on food reward but not food intake. Neuropharmacology 73: 274–283.PubMedGoogle Scholar
  35. 35.
    Perelló M, Zigman JM, 2012 The role of ghrelin in reward-based eating. Biol Psychiatry 72: 347–353.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Malik S, McGlone F, Bedrossian D, Dagher A, 2008 Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab 7: 400–409.PubMedGoogle Scholar
  37. 37.
    Disse E, Bussier A-L, Veyrat-Durebex C, et al, 2010 Peripheral ghrelin enhances sweet taste food consumption and preference, regardless of its caloric content. Physiol Behav 101: 277–281.PubMedGoogle Scholar
  38. 38.
    Finger B, Dinan T, Cryan J, 2012 Diet-induced obesity blunts the behavioural effects of ghrelin: studies in a mouse-progressive ratio task. Psychopharmacology (Berl) 220: 173–181.Google Scholar
  39. 39.
    Perello M, Sakata I, Birnbaum S, et al, 2010 Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent manner. Biol Psychiatry 67: 880–886.PubMedGoogle Scholar
  40. 40.
    Landgren S, Simms J, Thelle D, et al, 2011 The ghrelin signalling system is involved in the consumption of sweets. PLoS ONE 6: e18170.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Hillman JB, Tong J, Tschop M, 2011 Ghrelin biology and its role in weight-related disorders. Discov Med 11: 521.PubMedGoogle Scholar
  42. 42.
    Gil-Campos M, Aguilera CM, Ramirez-Tortosa MC, Cañete R, Gil A, 2010 Fasting and postprandial relationships among plasma leptin, ghrelin, and insulin in prepubertal obese children. Clin Nutr 29: 54–59.PubMedGoogle Scholar
  43. 43.
    Briggs DI, Enriori PJ, Lemus MB, Cowley MA, Andrews ZB, 2010 Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology 151: 4745.4755.Google Scholar
  44. 44.
    Ukkola O, Ravussin E, Jacobson P, et al, 2001 Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab 86: 3996–3999.PubMedGoogle Scholar
  45. 45.
    Korbonits M, Gueorguiev M, O’Grady E, et al, 2002 A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab 87: 4005–4008.PubMedGoogle Scholar
  46. 46.
    Leskelä P, Ukkola O, Vartiainen J, et al, 2009 Fasting plasma total ghrelin concentrations in monozygotic twins discordant for obesity. Metabolism 58: 174–179.PubMedGoogle Scholar
  47. 47.
    Baessler A, Hasinoff MJ, Fischer M, et al, 2005 Genetic linkage and association of the growth hormone secretagogue receptor (ghrelin receptor) gene in human obesity. Diabetes 54: 259–267.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Garcia EA, Heude B, Petry CJ, et al, 2008 Ghrelin receptor gene polymorphisms and body size in children and adults. J Clin Endocrinol Metab 93: 4158–4161.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Pugliese-Pires PN, Fortin J-P, Arthur T, et al, 2011 Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty. Eur J Endocrinol 165: 233–241.PubMedGoogle Scholar
  50. 50.
    Ma X, Lin Y, Lin L, et al, 2012 Ablation of ghrelin receptor in leptin-deficient ob/ob mice has paradoxical effects on glucose homeostasis when compared with ablation of ghrelin in ob/ob mice. Am J Physiol Endocrinol Metab 303: E422–E431.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Saeed S, Bech P, Hafeez T, et al, 2013 Changes in levels of peripheral hormones controlling appetite are inconsistent with hyperphagia in leptin-deficient subjects. Endocrine 45: 401–408.PubMedGoogle Scholar
  52. 52.
    Cole SA, Butte NF, Voruganti VS, et al, 2010 Evidence that multiple genetic variants of MC4R play a functional role in the regulation of energy expenditure and appetite in Hispanic children. Am J Clin Nutr 91: 191–199.PubMedGoogle Scholar
  53. 53.
    Karra E, O’Daly OG, Choudhury AI, et al, 2013 A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest 123: 3539–3551.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Benedict C, Axelsson T, Söderberg S, et al, 2014 Brief communication: The fat mass and obesity-associated gene (FTO) is linked to higher plasma levels of the hunger hormone ghrelin and lower serum levels of the satiety hormone leptin in older adults. Diabetes 63: 3955–3959.PubMedGoogle Scholar
  55. 55.
    Nicholls RD, Knepper JL, 2001 Genome organization, function, and imprinting in Prader-Willi and Angelman Syndromes. Annu Rev Genomics Hum Genet 2: 153–175.PubMedGoogle Scholar
  56. 56.
    Bieth E, Eddiry S, Gaston V, et al, 2014 Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi Syndrome. Eur J Hum Genet: doi: 10.1038/ejhg.Google Scholar
  57. 57.
    Cummings DE, Weigle DS, Frayo RS, et al, 2002 Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346: 1623–1630.PubMedGoogle Scholar
  58. 58.
    Haqq AM, Farooqi IS, O’Rahilly S, et al, 2003 Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi Syndrome. J Clin Endocrinol Metab 88: 174–178.PubMedGoogle Scholar
  59. 59.
    DelParigi A, Tschöp M, Heiman ML, et al, 2002 High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi Syndrome. J Clin Endocrinol Metab 87: 5461–5464.PubMedGoogle Scholar
  60. 60.
    Goldstone AP, Holland AJ, Butler JV, Whittington JE, 2012 Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes 36: 1564–1570.Google Scholar
  61. 61.
    Scerif M, Goldstone AP, Korbonits M, 2011 Ghrelin in obesity and endocrine diseases. Mol Cell Endocrinol 340: 15–25.PubMedGoogle Scholar
  62. 62.
    Choe YH, Song SY, Paik K-H, et al, 2005 Increased density of ghrelin-expressing cells in the gastric fundus and body in Prader-Willi Syndrome. J Clin Endocrinol Metab 90: 5441–5445.PubMedGoogle Scholar
  63. 63.
    Kojima M, Kangawa K, 2005 Ghrelin: Structure and Function. Physiol Rev 85: 495–522.PubMedGoogle Scholar
  64. 64.
    Goldstone AP, 2004 Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 15: 12–20.PubMedGoogle Scholar
  65. 65.
    Higgins S, Gueorguiev M, Korbonits M, 2007 Ghrelin, the peripheral hunger hormone. Ann Med 39: 116–136.PubMedGoogle Scholar
  66. 66.
    Feigerlová E, Diene G, Conte-Auriol F, et al, 2008 Hyperghrelinemia precedes obesity in Prader-Willi Syndrome. J Clin Endocrinol Metab 93: 2800–2805.PubMedGoogle Scholar
  67. 67.
    Bizzarri C, Rigamonti AE, Luce A, et al, 2010 Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. Eur J Endocrinol 162: 499–505.PubMedGoogle Scholar
  68. 68.
    Purtell L, Sze L, Loughnan G, et al, 2011 In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. Neuropeptides 45: 301–307.PubMedGoogle Scholar
  69. 69.
    Morris J, Twaddle S, 2007 Anorexia nervosa. BMJ 334: 894–898.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Hoek HW, 2006 Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. Curr Opin Psychiatry 19: 389–394.PubMedGoogle Scholar
  71. 71.
    Monteleone P, Serritella C, Martiadis V, Scognamiglio P, Maj M, 2008 Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. J Clin Endocrinol Metab 93: 4418–4421.PubMedGoogle Scholar
  72. 72.
    Nedvidková J, Krykorková I, Barták V, et al, 2003 Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J Clin Endocrinol Metab 88: 1678–1682.PubMedGoogle Scholar
  73. 73.
    Tolle V, Kadem M, Bluet-Pajot M-T, et al, 2003 Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 88: 109–116.PubMedGoogle Scholar
  74. 74.
    Miljic D, Pekic S, Djurovic M, et al, 2006 Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and Cortisol release in patients with anorexia nervosa. J Clin Endocrinol Metab 91: 1491–1495.PubMedGoogle Scholar
  75. 75.
    Asakawa A, Inui A, Fujimiya M, et al, 2005 Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54: 18–24.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Koyama KI, Yasuhara D, Nakahara T, et al, 2010 Changes in acyl ghrelin, des-acyl ghrelin, and ratio of acyl ghrelin to total ghrelin with short-term refeeding in female inpatients with restricting-type anorexia nervosa. Horm Metab Res 42: 595–598.PubMedGoogle Scholar
  77. 77.
    Terashi M, Asakawa A, Harada T, et al, 2011 Ghrelin reactive autoantibodies in restrictive anorexia nervosa. Nutrition 27: 407–413.PubMedGoogle Scholar
  78. 78.
    Sedlackova D, Kopeckova J, Papezova H, et al, 2012 Comparison of a high-carbohydrate and high-protein breakfast effect on plasma ghrelin, obestatin, NPY and PYY levels in women with anorexia and bulimia nervosa. Nutr Metab 9: 52.Google Scholar
  79. 79.
    Germain N, Galusca B, Grouselle D, et al, 2010 Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. J Clin Endocrinol Metab 95: 3057–3062.PubMedGoogle Scholar
  80. 80.
    Dardennes RM, Zizzari P, Tolle V, et al, 2007 Family trios analysis of common polymorphisms in the obestatin/ghrelin, BDNF and AGRP genes in patients with Anorexia nervosa: Association with subtype, body-mass index, severity and age of onset. Psychoneuroendocrinology 32: 106–113.PubMedGoogle Scholar
  81. 81.
    Müller TD, Tschöp MH, Jarick I, et al, 2011 Genetic variation of the ghrelin activator gene ghrelin O-acyltransferase (GOAT) is associated with anorexia nervosa. J Psychiatr Res 45: 706–711.PubMedGoogle Scholar
  82. 82.
    Ando T, Komaki G, Nishimura H, et al, 2010 A ghrelin gene variant may predict crossover rate from restricting-type anorexia nervosa to other phenotypes of eating disorders: a retrospective survival analysis. Psychiatr Genet 20: 153–159.PubMedGoogle Scholar
  83. 83.
    Kindler J, Bailer U, de Zwaan M, et al, 2011 No association of the neuropeptide Y (Leu7Pro) and ghrelin gene (Arg51Gln, Leu72Met, Gln90Leu) single nucleotide polymorphisms with eating disorders. Nord J Psychiatry 65: 203–207.PubMedGoogle Scholar
  84. 84.
    APA 2000 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington.Google Scholar
  85. 85.
    Tanaka M, Naruo T, Muranaga T, et al, 2002 Increased fasting plasma ghrelin levels in patients with bulimia nervosa. Eur J Endocrinol 146: R1–R3.PubMedGoogle Scholar
  86. 86.
    Kojima S, Nakahara T, Nagai N, et al, 2005 Altered ghrelin and peptide YY responses to meals in bulimia nervosa. Clin Endocrinol (Oxf) 62: 74–78.Google Scholar
  87. 87.
    Nakazato M, Hashimoto K, Shiina A, et al, 2004 No changes in serum ghrelin levels in female patients with bulimia nervosa. Prog Neuropsychopharmacol Biol Psychiatry 28: 1181–1184.PubMedGoogle Scholar
  88. 88.
    Atalayer D, Gibson C, Konopacka A, Geliebter A, 2013 Ghrelin and eating disorders. Prog Neuropsychopharmacol Biol Psychiatry 40: 70–82.PubMedGoogle Scholar
  89. 89.
    Cano S, Merkestein M, Skibicka K, Dickson S, Adan RH, 2012 Role of ghrelin in the pathophysiology of eating disorders. CNS Drugs 26: 281–296.Google Scholar
  90. 90.
    Troisi A, Di Lorenzo G, Lega I, et al, 2005 Plasma ghrelin in anorexia, bulimia, and binge-eating disorder: Relations with eating patterns and circulating concentrations of Cortisol and thyroid hormones. Neuroendocrinology 81: 259–266.PubMedGoogle Scholar
  91. 91.
    Miyasaka K, Hosoya H, Sekime A, et al, 2006 Association of ghrelin receptor gene polymorphism with bulimia nervosa in a Japanese population. J Neural Transm 113: 1279–1285.PubMedGoogle Scholar
  92. 92.
    Evans WJ, Morley JE, Argilés J, et al, 2008 Cachexia: a new definition. Clin Nutr 27: 793–799.PubMedGoogle Scholar
  93. 93.
    Ashitani J, Matsumoto N, Nakazato M, 2009 Ghrelin and its therapeutic potential for cachectic patients. Peptides 30: 1951–1956.PubMedGoogle Scholar
  94. 94.
    Sharma R, Anker S, 2001 First cachexia symposium, Berlin, Germany, 1st–2nd December, 2000. Eur J Heart Fail 3: 751–754.PubMedGoogle Scholar
  95. 95.
    Itoh T, Nagaya N, Yoshikawa M, et al, 2004 Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 879–882.PubMedGoogle Scholar
  96. 96.
    Huang Q, Fan YZ, Ge BJ, Zhu Q, Tu ZY, 2007 Circulating ghrelin in patients with gastric or colorectal cancer. Dig Dis Sci 52: 803–809.PubMedGoogle Scholar
  97. 97.
    Wolf I, Sadetzki S, Kanety H, et al, 2006 Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106: 966–973.PubMedGoogle Scholar
  98. 98.
    Nikolopoulos D, Theocharis S, Kouraklis G, 2010 Ghrelin: A potential therapeutic target for cancer. Regul Pept 163: 7–17.PubMedGoogle Scholar
  99. 99.
    Aygen B, Dogukan A, Dursun F, et al, 2009 Ghrelin and obestatin levels in end-stage renal disease. J Int Med Res 37: 757–765.PubMedGoogle Scholar
  100. 100.
    Yoshimoto A, Mori K, Sugawara A, et al, 2002 Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 13: 2748–2752.PubMedGoogle Scholar
  101. 101.
    Garin MC, Burns CM, Kaul S, Cappola AR, 2013 The human experience with ghrelin administration. J Clin Endocrinol Metab 98: 1826–1837.PubMedPubMedCentralGoogle Scholar
  102. 102.
    Broglio F, Gianotti L, Destefanis S, et al, 2004 The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol (Oxf) 60: 592–599.Google Scholar
  103. 103.
    Hotta M, Ohwada R, Akamizu T, et al, 2009 Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: A pilot study. Endocr J 56: 1119–1128.PubMedGoogle Scholar
  104. 104.
    Nagaya N, Moriya J, Yasumura Y, et al, 2004 Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110: 3674–3679.PubMedGoogle Scholar
  105. 105.
    Nagaya N, Itoh T, Murakami S, et al, 2005 Treatment of cachexia with ghrelin in patients with copd. Chest 128: 1187–1193.PubMedGoogle Scholar
  106. 106.
    Wynne K, Giannitsopoulou K, Small CJ, et al, 2005 Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: A randomized, placebo-controlled trial. J Am Soc Nephrol 16: 2111–2118.PubMedGoogle Scholar
  107. 107.
    Neary NM, Small CJ, Wren AM, et al, 2004 Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89: 2832–2836.PubMedGoogle Scholar
  108. 108.
    Akamizu T, Kangawa K, 2011 Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect. Peptides 32: 2295–2300.PubMedGoogle Scholar
  109. 109.
    Porporato PE, Filigheddu N, Reano S, et al, 2013 Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 123: 611–622.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Özcan B, Neggers SJ, Miller AR, et al, 2013 Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels? Eur J Endocrinol 170: 799–807.PubMedGoogle Scholar
  111. 111.
    Broglio F, Gottero C, Prodam F, et al, 2004 Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 89: 3062–3065.PubMedGoogle Scholar
  112. 112.
    Benso A, St-Pierre DH, Prodam F, et al, 2012 Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. Eur J Endocrinol 166: 911–916.PubMedGoogle Scholar
  113. 113.
    Ejskjaer N, Wo JM, Esfandyari T, et al, 2013 A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 25: e140–e150.PubMedGoogle Scholar
  114. 114.
    Depoortere I, 2009 Targeting the ghrelin receptor to regulate food intake. Regul Pept 156: 13–23.PubMedGoogle Scholar
  115. 115.
    Palus S, Schur R, Akashi YJ, et al, 2011 Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS ONE 6: e26865.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Lenk K, Palus S, Schur R, et al, 2013 Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle 4: 63–69.PubMedGoogle Scholar
  117. 117.
    Garcia JM, Polvino WJ, 2007 Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: Results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12: 594–600.PubMedGoogle Scholar
  118. 118.
    Beck B, Richy S, Stricker-Krongrad A, 2004 Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci 76: 473–478.PubMedGoogle Scholar
  119. 119.
    Asakawa A, Inui A, Kaga T, et al, 2003 Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52: 947–952.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Esler WP, Rudolph J, Claus TH, et al, 2007 Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148: 5175–5185.PubMedGoogle Scholar
  121. 121.
    Delporte C, 2012 Recent advances in potential clinical application of ghrelin in obesity. J Obes 2012: doi: 10.1155/2012/535624.Google Scholar
  122. 122.
    Holst B, Lang M, Brandt E, et al, 2006 Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol Pharmacol 70: 936–946.PubMedGoogle Scholar
  123. 123.
    Barnett BP, Hwang Y, Taylor MS, et al, 2010 Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science 330: 1689–1692.PubMedPubMedCentralGoogle Scholar
  124. 124.
    Yang TJ, Zhao TJ, Goldstein JL, Brown MS, 2008 Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A 105: 10750–10755.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Janssen S, Laermans J, Verhulst PJ, et al, 2011 Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying. Proc Natl Acad Sci U S A 108: 2094–2099.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Nørrelund H, Hansen TK, Ørskov H, et al, 2002 Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 57: 539–546.Google Scholar
  127. 127.
    Haqq AM, Stadler DD, Rosenfeld RG, et al, 2003 Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi Syndrome. J Clin Endocrinol Metab 88: 3573–3576.PubMedGoogle Scholar
  128. 128.
    De Waele K, Ishkanian SL, Bogarin R, et al, 2008 Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur J Endocrinol 159: 381–388.PubMedGoogle Scholar
  129. 129.
    Takeda H, Muto S, Nakagawa K, et al 2012 Chapter Twenty-One — Rikkunshito as a ghrelin enhancer. In: K Masayasu and K Kenji (eds) Methods in Enzymology, Academic Press; pp, 333–351.Google Scholar
  130. 130.
    Matsumura T, Arai M, Yonemitsu Y, et al, 2010 The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol 45: 300–307.PubMedGoogle Scholar
  131. 131.
    Takeda H, Muto S, Hattori T, et al, 2010 Rikkunshito ameliorates the aging-associated decrease in ghrelin receptor reactivity via phosphodiesterase III inhibition. Endocrinology 151: 244–252.PubMedGoogle Scholar
  132. 132.
    Zorrilla EP, Iwasaki S, Moss JA, et al, 2006 Vaccination against weight gain. Proc Natl Acad Sci U S A 103: 13226–13231.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Andrade S, Carreira MC, Ribeiro A, et al, 2011 Development of an anti-ghrelin vaccine for obesity treatment. Endocr Rev 32: P2–305.Google Scholar
  134. 134.
    Lu SC, Xu J, Chinookoswong N, et al, 2009 An acylghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. Mol Pharmacol 75: 901–907.PubMedGoogle Scholar
  135. 135.
    Cytos Biotechnology 2006. Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss. https://doi.org/www.cytos.com/uploads/news/id180/CytosPressE061107.pdf Accessed 22nd September 2014.
  136. 136.
    Monteiro MP, 2011 Anti-ghrelin vaccine for obesity: a feasible alternative to dieting? Expert Rev Vaccines 10: 1363–1365.PubMedGoogle Scholar
  137. 137.
    Shearman LP, Wang SP, Helmling S, et al, 2006 Ghrelin neutralization by a Ribonucleic Acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147: 1517–1526.PubMedGoogle Scholar
  138. 138.
    Becskei C, Bilik KU, Klussmann S, et al, 2008 The anti-ghrelin spiegelmer NOX-B11-3 blocks ghrelin-but not fasting-induced neuronal activation in the hypothalamic arcuate nucleus. J Neuroendocrinol 20: 85–92.PubMedGoogle Scholar
  139. 139.
    Helmling S, Maasch C, Eulberg D, et al, 2004 Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci U S A 101: 13174–13179.PubMedPubMedCentralGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2014

Authors and Affiliations

  1. 1.Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of MedicineQueen Mary University of LondonLondonUK

Personalised recommendations